Name : Human Complement Component C1s Protein
Product Source :
Recombinant Human Complement Component C1s Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Glu16-Asp688.[Accession | P09871]
Molecular Weight :
The protein has a predicted MW of 75.98 kDa. Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human Complement Component C1s on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Human Complement Component C1S, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-C1S Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA.
Background :
Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS).
Synonyms :
Complement C1s subcomponent; C1 esterase;
References & Citations :
Subasinghe NL, Khalil E, Travins JM, Ali F, Ballentine SK, Hufnagel HR, Pan W, Leonard K, Bone RF, Soll RM, Crysler CS, Ninan N, Kirkpatrick J, Kolpak MX, Diloreto KA, Eisennagel SH, Huebert ND, Molloy CJ, Tomczuk BE, Gaul MD. Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2012 Aug 15;22(16):5303-7. doi: 10.1016/j.bmcl.2012.06.030. Epub 2012 Jun 16. PMID: 22795627.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
EGF Proteinsupplier
Animal-Free FGF-12 ProteinMedChemExpress
Popular categories:
Eotaxin/CCL11
CD40 Ligand/CD154